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Identity 
Other names: Deep 'aggressive' angiomyxoma 
Note: The term aggressive was introduced to 
emphasize the locally aggressive behaviour and the 
high potential for local recurrence, it does not reflect a 
high probability for metastasis, as only 2 cases with 
metastatic disease have been reported. The name 
angiomyxoma was chosen because of the similarity to 
myxoma and the notable vascular component. 
Classification 
Aggressive angiomyxoma (AA) is a soft tissue 
neoplasm. The term AA was not coined until 1983 but 
similar tumours were described as early as in the 
1860ies. In the latest WHO-classification AA is now 
classified under 'Tumours of uncertain differentiation'. 
Clinics and pathology 
Disease 
AA is a neoplasm. It is defined as benign but has 
infiltrative potential into skeletal muscle and fat. The 
disease is therefore considered locally aggressive 
although it does not infiltrate surrounding viscus. Only 
2 cases with metastatic disease have been published. 
Etiology 
No etiologic factors are known. 
Epidemiology 
AA is a rare neoplasm with about 150 reported cases. It 
is most often found in women in reproductive age with 
a peak incidence in the fourth decade of life. The 
female:male ratio is 6:1. 
 
Clinics 
AA is most often found in or in proximity to the lower 
pelvis, more specifically perineum, vulva, vagina or 
inguinal regions. The majority of patients present with 
a slow-growing mass which is otherwise asymptomatic 
and this is frequently the only symptom/sign. Observed 
accompanying symptoms and signs are regional pain, a 
feeling of local pressure, or dyspareunia. Tumour size 
is often underestimated by physical examination. It is 
worth noticing that the frequency of symptoms and 
signs attributable to local growth is lower than what 
would be expected from the relatively large size of 
most of these tumours. AA is often clinically 
misdiagnosed, most often mistaken for a Bartholin cyst. 
Radiographically, AA is isointense or has low signal 
intensity on T1-weighted MRI, and have a whorled 
pattern of high signal intensity on T2-weighted MRI. 
These tumours show contrast enhancement, reflecting 
their inherent vasculature, and tend to displace and 
grow around structures rather than infiltrate them. 
Pathology 
Most AA are big, often more than 10 cm in largest 
diameter. These tumours are macroscopically lobulated 
and may adhere to surrounding soft tissue. 
Microscopically, cells with a spindled or stellate 
morphology are seen, embedded in a loose matrix 
consisting of wavy collagen and oedema. Cellularity is 
generally low to moderate. Infiltration into fat, muscle, 
and nerves is seen. The hallmark of AA is vessels of 
varying calibre haphazardly scattered throughout the 
tumour parenchyma, whereas mitotic figures are scarce. 
Immunohistochemically, most AA are positive for 
desmin, smooth muscle actin, muscle-specific actin, 
vimentin, oestrogen receptor, and progesterone 
receptor.  
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Some tumours are positive for CD34, whereas S100 is 
invariably negative. Based on these observations, a 
myofibroblastic differentiation of the neoplastic cells is 
suggested. 
Treatment 
Radical surgery with wide margins is the treatment of 
choice. Because most tumours are large, grow 
infiltrative and blends with adjacent soft tissue, and are 
located in close proximity to vital organs such as 
bladder and rectum, wide excision is not always 
possible and/or may cause significant morbidity. In 
such situations watchful waiting may be advisable 
because these tumours may be stable with no or very 
limited growth over long periods of time. Several 
reported attempts using chemotherapy and radiotherapy 
as part of the treatment for AA have been 
disappointing, probably due to the low mitotic 
activity/growth fraction of cells. Most AA express 
oestrogen and progesterone receptors and are likely to 
have a hormone-dependent growth. Because of this, 
treatment with GnRH agonists has been administered to 
AA patients, and some case reports with dramatic 
responses to such GnRH agonists have been reported. 
Prognosis 
The prognosis is very good. Only 2 cases with 
metastatic disease followed by death have been 
reported. Recurrences are common, though, reported to 
be between 9 and 72 %. These numbers are uncertain 
because late recurrences may develop several years 
after the primary tumour was found, and long-term 
follow-up of the patients is therefore very important. 
The major problem posed by this tumour is the often 
mutilating surgery necessary to cure the patient. 
Cytogenetics 
Cytogenetics morphological 
Although only 6 cases of AA showing chromosomal 
aberrations have been described so far, a non-random 
involvement of chromosomal band 12q15 has been 
identified. The cytogenetic rearrangements hitherto 
described, involving this band, are: t(11;12)(q23;q15), 
t(7;12)(q22;q13-14), t(8;12)(p12;q15), and 
der(12)t(5;12)(q31;p11)inv(12)(p11q14). An additional 
case with 12q15 rearrangement has been described 
using fluorescence in situ hybridization. 
Cytogenetics molecular 
The 12q15 rearrangements lead to alterations of the 
high mobility group (HMG) gene HMGA2 (previously 
known as HMGIC). 
Additional anomalies 
Monosomy of the X chromosome has been reported in 
one AA, whereas another AA showed monosomy 12 
among other abnormalities. 
 
 
Ideograms and G-banded images of chromosomes 11 and 12 
from an AA are depicted. Normal chromosome homologs and 
rearranged chromosomes are shown. Arrows indicate 
breakpoint positions. 




The HMGA2 gene consists of 5 exons spanning 141 kb 
of genomic DNA. It is highly expressed in embryonic 
tissue. In normal adult tissues, only low gene 
expression levels have been detected, and only in 
kidney, lung, and synovia. In all other terminally 
differentiated cells, no expression of this gene has been 
detected. 
Protein 
The HMGA2 gene encodes a member of the high-
mobility group A (HMGA) of small, non-histonic, 
chromatin-associated proteins. These proteins are 
believed to affect transcription in several ways. They 
act as architectural elements by bending the DNA, they 
interact with a large number of other proteins, mainly 
transcription factors, and they also influence upon 
chromatin changes during cell cycle. As all proteins in 
this family, HMGA2 contains three copies of a 
conserved DNA-binding peptide motif called AT-hook. 
This AT-hook preferentially binds to the minor groove 
of stretches of AT-rich sequences. 
Somatic mutations: 
Increased protein levels of HMGA2 have been reported 
in a variety of benign mesenchymal tumours, including 
lipoma, leiomyoma, chondroid tumours, pulmonary 
hamartoma, endometrial polyps, and fibroadenoma of  
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the breast. In all these neoplasms rearrangements of 
chromosomal band 12q15 have been found at the 
cytogenetic resolution level. 




In general, two types of HMGA2 rearrangement are 
known. In some cases, HMGA2 is interrupted after the 
end of the third exon, whereby the AT hook domains 
are separated from the 3’ portion of the gene. This 3’ 
portion of the gene, coding for the protein-binding 
domains of HMGA2, is thereby lost. In other cases, 
breakpoints outside the coding region of the gene are 
found. These extragenic breaks suggest a disruption of 
regulatory sequences, which lead to abnormal 
expression of HMGA2. Expression of the entire 
HMGA2 gene is achieved through alterations affecting 
5’ regulatory elements or the 3’ untranslated region, 
leading to a stabilized mRNA. It is important to note 
that even if the fusion products mentioned above are in-
frame, some of HMGA2’s partner genes contribute 
with very few amino acids to the chimeric product. It 
has therefore been suggested that the minimal 
requirement for tumourigenesis would be activating 
HMGA2 rearrangements leaving at least exons 1-3 of 
HMGA2 intact. For the specific translocation 
t(11;12)(q23;q15), the result is the abnormal expression 
of an intact, full-length product of HMGA2. 
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